Previous Article | Next Article ![]()
Molecular and Cellular Biology, March 2002, p. 1438-1445, Vol. 22, No. 5
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.5.1438-1445.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Institute of Pathology, University Hospital RWTH, D-52074 Aachen,1 Institute of Pathology, University of Bonn, D-53127 Bonn, Germany,5 M. E. Müller-Institut for Biomechanics, University of Bern, CH-010 Bern, Switzerland,2 Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri 63110,3 Department of Experimental Pathology, Lund University, S-22185 Lund, Sweden4
Received 31 July 2001/ Returned for modification 31 August 2001/ Accepted 19 November 2001
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Recently, the three-dimensional structure of MIA/CD-RAP has been determined by multidimensional nuclear magnetic resonance spectroscopy (22) and determined independently by X-ray crystallography (14). The corresponding data indicate that MIA/CD-RAP defines a novel family of secreted proteins which adopt an SH3 domain-like fold in solution. Furthermore, nuclear magnetic resonance spectra revealed that MIA interacts with peptides matching type III human fibronectin repeats which are closely related to
4ß1 integrin binding sites (22). These data support a model in which MIA/CD-RAP regulates attachment to specific components of the extracellular matrix.
In nonneoplastic tissues, MIA/CD-RAP expression is activated at the beginning of chondrogenesis throughout cartilage development (4, 8), and in vitro, it is a specific marker for chondroid differentiation. Cartilage damage due to rheumatoid arthritis releases MIA/CD-RAP from the chondroid matrix and can be monitored clinically by enhanced MIA/CD-RAP in serum (17). Based on its highly restricted activity (2), the MIA/CD-RAP promoter was used to study transcriptional mechanisms mediating chondrocyte differentiation. A 2,251-bp fragment of the murine MIA/CD-RAP 5'-end-flanking sequence contains all known functionally important trancriptional regulatory elements, including melanoma-associated transcription factor (10), AP-2, and Sox9 binding sites (19, 25, 26), and was sufficient to confer tissue-specific expression in vivo. Expression of a LacZ reporter under the control of the 2,251-bp MIA/CD-RAP promoter was observed exclusively in cartilage and transiently in embryonic mammary buds (27). These data suggested that MIA/CD-RAP may be functionally important for cartilage differentiation and for specific morphogenetic events during embryogenesis involving invasive growth.
To study the consequences of MIA/CD-RAP deficiency in vivo, we inactivated the gene by targeted germline mutation. Data described in this study indicate that MIA/CD-RAP function is required for the highly ordered fibrillar ultrastructure of cartilage but may be redundant in other tissues.
| MATERIALS AND METHODS |
|---|
|
|
|---|
For routine genotyping of the MIA breeding pairs, genomic-tail DNA was prepared and analyzed by PCR. The primer pair to amplify the wild-type allele was MIA-wt sense (5'-ATC CTA TCT CCA TGG CTG TGG-3') and MIA-wt anti (5'-GCC ACT TTT GAT GGT TTG CTG G-3"). The primer pair to amplify the targeted allele was MIA-ko anti (5"-CCC ATC AGC CTC ACC GTA GGT-3") and PGK-polyA down (5"-CGT CTC TTT ACT GAA GGC TCT TT-3").
Cell culture. Chondrocytes were isolated from the sternums of heterozygous and MIA-deficient mice by digestion with hyaluronidase, collagenase, and DNase. Cells were cultivated in Dulbecco modified Eagle medium (DMEM) supplemented with penicillin (100 U/ml), streptomycin (10 µg/ml) (Sigma, Deisenhofen, Germany), and 10% fetal calf serum (Gibco BRL) in a humified atmosphere of 5% CO2 at 37°C and split 1:2 at 80% confluence. To induce redifferentiation, cells were treated with transforming growth factor ß for 4 days.
RNA isolation and RT-PCR. For reverse transcription-PCR (RT-PCR), total cellular RNA was isolated from three cryosections of each embryo (100 µm) or from cultivated chondrocytes with an RNeasy kit (Qiagen, Hilden, Germany). The integrity of the RNA preparations was controlled on a 1% agarose-formaldehyde gel. The reverse transcriptase reaction was performed in a 20-µl reaction volume containing 2 µg of total cellular RNA, 4 µl of 5x first-strand buffer (Gibco BRL), 2 µl of 0.1 M dithiothreitol, 1 µl of the dN6 primer (10 mM), 1 µl of the deoxynucleoside triphosphates (10 mM), and diethyl pyrocarbonate-water. The reaction mix was incubated for 10 min at 70°C. Then, 1 µl of Superscript II reverse transcriptase (Gibco BRL) was added and RNAs were transcribed for 1 h at 37°C. Subsequently, reverse transcriptase was inactivated at 70°C for 10 min and RNA was degraded by digestion with 1 µl of RNase A (10 mg/ml) at 37°C for 30 min. cDNAs were controlled by PCR amplification of ß-actin. MIA was amplified by PCR with specific primers, resulting in a 311-bp fragment (mMIA for [5'-CTG GCT GAC CGG AAG CTG TG-3'] and mMIA rev [5'-GCT ACT GGG GAA ATA GCC C-5"]). Next, TANGO, OTOR, MIA2, and type I and II collagens were amplified. PCRs were performed in a 100-µl reaction volume containing 1 µl of cDNA, 10 µl of 10x PCR buffer, 1 µl of the deoxynucleoside triphosphates, 1 µl of each primer, and 1 µl of Taq polymerase (Roche, Mannheim, Germany). The amplification reactions were performed with 30 repetitive cycles of denaturing for 1 min at 94°C and annealing for 1 min at 58°C and a final extension step at 72°C for 1.5 min. The PCR products were resolved on 1.8% agarose gels.
ISH. In situ hybridization (ISH) to paraffin-embedded mouse hindlimbs on day 1 postnatalis (p.n.) was performed as described previously (15) using 33P-labeled sense and antisense cRNA riboprobes (4). Briefly, proteinase K-pretreated slides (10 µg/ml) were acetylated in acetic anhydride diluted 1:400 in 0.1 M triethanolamine (pH 8) and hybridized overnight in 50% formamide-10% dextran sulfate-10 mM Tris (pH 8)-10 mM NaPi (pH 7)-2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-5 mM EDTA (pH 8)-150 µg of tRNA/ml-10 mM dithiothreitol-10 mM ß-mercaptoethanol supplemented with 5 x 104 cpm of 33P-labeled sense or antisense riboprobes/µl at 50°C. Finally, slides were washed twice in 50% formamide-2x SSC-20 mM ß-mercaptoethanol, digested with RNase A (20 µg/ml) for 30 min at 37°C, and then washed again three times with the same washing buffer for 30 min each at 50°C. Following dehydration, slides were coated with Kodak (Rochester, N.Y.) NTB2 emulsion and exposed for 8 to 10 days.
Skeletal staining. Skeletal staining of whole mouse embryos was performed 15.5 days postcoitum as described previously (24). In brief, whole embryos were fixed for 5 days in 95% ethanol and transferred to acetone for 2 days. Staining was performed with 0.005% alzarin red S-0.015% alcian blue 8GS-5% acetic acid-90% ethanol for 3 days at 37°C. Samples were washed in H2O and cleared for 2 days in 1% KOH, followed by clearing steps in 0.8% KOH-20% glycerol, in 0.5% KOH-50% glycerol, and in 0.2% KOH-80% glycerol for 1 week each. Cleared skeletons were stored in 100% glycerol and photographed.
Western blots. Three cryosections of each embryo (100 µm) were lysed in 200 µl of radioimmunoprecipitation assay buffer (Roche), and protein concentrations were determined using the bicinchoninic acid protein assay reagent (Pierce, Bonn, Germany). Twenty micrograms of protein per lane was denatured at 94°C for 10 min after the addition of Roti load buffer (Roth, Karlsruhe, Germany) and subsequently separated on 4 to 20%-gradient sodium dodecyl sulfate-polyacrylamide electrophoresis gels. After we transferred the proteins by Western blotting onto polyvinylidene difluoride membranes (Bio-Rad, Richmond, Calif.), the membranes were blocked in 3% bovine serum albumin-phosphate-buffered saline for 1 h and incubated with a 1:30 dilution of primary polyclonal anti-MIA antibody overnight at 4°C. A 1:300 dilution of rabbit anti-immunoglobulin G coupled to alkaline phosphatase (Roche) was used as secondary antibody. Staining was performed with BCIP (5-bromo-4-chloro-indolylphosphate)-nitroblue tetrazolium tablets (Sigma).
MIA ELISA. MIA expression was measured by a one-step enzyme-linked immunosorbent assay (ELISA) of the lysates of the mouse embryos. Two monoclonal antibodies (MAbs) directed against 14-meric N-terminal and C-terminal peptides (MAb 1A12 and MAb 2F7; Roche) were raised and conjugated to horseradish peroxidase and biotin, respectively. Twenty microliters of lysate was coincubated with biotinylated MAb 2F7 and horseradish peroxidase-conjugated MAb 1A12 in streptavidin-coated 96-well plates for 45 min. After the wells were washed three times with phosphate-buffered saline, 200 µl of ABTS solution (2,2"-azino-di-[3-ethylbenzthiazoline sulfonate(6)]; Roche) was incubated in the wells for 30 min and measured colorimetrically at a wavelength of 405 nm. By using standard concentrations of recombinant MIA purified from stably transfected CHO cells, we measured linear signals at MIA concentrations between 0.1 and 50 ng/ml.
Immunohistochemistry. Paraffin-embedded preparations of newborn wild-type and MIA-/- mice were immunostained with collagen type I- and type II-specific antibodies using the avidin-biotin complex method (LSAB2 kit; DAKO, Hamburg, Germany). The tissues were deparaffinated, rehydrated, and subsequently incubated with primary MAbs (both diluted 1:100; ICN) overnight at 4°C. The secondary antibody supplied with the kit was incubated for 30 min at room temperature. Antibody binding was visualized with 3-amino-9-ethylcarbazole solution (for the LSAB2 kit). Finally, the tissues were counterstained with hematoxylin.
Electron microscopy. The articular cartilage of the femoral and tibial portions of the knee joints of control and null mice were chemically fixed in an aqueous solution of glutaraldehyde (2.5%) in 0.1 M sodium cacodylate buffer (pH 7.4). Following fixation at room temperature over 2 days, postfixation was started with a 1% osmium tetroxide solution (sodium cacodylate buffer, pH 7.4) over a period of 4 h at room temperature and then over 20 h at 4°C. Thereafter, specimens were washed four times in isotonic sodium cacodylate buffer (0.1 M; pH 7.4) and dehydrated through a graded series of ethanol starting at 70% (vol/vol) over a total time period of 3 h. Thereafter, embedding was initiated in Epon 812 with polypropylene oxide-Epon mixtures over a period of 9 days. Polymerization was performed at 60°C over 1 week. One-micrometer semithin sections for light microscopic examination were cut with a Leica Ultracut S microtome and stained with toluidine blue 0. Thin sections were cut on the same instrument at a thickness of about 60 nm and stained with uranyl acetate and lead citrate according to standard protocols (12, 13).
Pericellular-territorial and interterritorial matrix compartments were analyzed separately. Matrix compartments were defined as described previously (9).
| RESULTS |
|---|
|
|
|---|
|
|
Skeletal preparations of E15.5 wild-type and knockout animals revealed normal development and gross morphology of the skeletal system, indicating undisturbed chondrogenesis and regular enchondral and desmal ossification (Fig. 3A). In addition, light microscopic examination of histological slides stained with hematoxylin, eosin, and alcian blue and analysis of MIA/CD-RAP expression by ISH revealed no pathological alteration in hyaline or fibrous cartilage (Fig. 2A and data not shown). Immunhistochemical stainings of tibia and femur sections showed identical patterns of type II collagen distribution and the absence of type I collagen in MIA/CD-RAP-deficient and wild-type cartilage (Fig. 3B). Further expression of type X collagen and aggrecan remained unchanged in knockout mice compared to that of wild-type littermates (data not shown).
|
As shown by representative electron micrographs in Fig. 4, increased sizes and irregular arrangement of fibers were observed in MIA/CD-RAP-defective cartilage. In both the pericellular-territorial and interterritorial matrix compartments, we detected significant irregularities in collagen fiber density, diameter, and arrangement, as well as changes in the number and morphology of chondrocytic microvilli. A detailed overview of electron microscopic findings is summarized in Table 1.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Very recently we detected that MIA/CD-RAP belongs to a family of four homologous and evolutionarily conserved proteins, MIA/CD-RAP, OTOR/MIAL (7, 18), MIA-2, and TANGO (Bosserhoff et al., submitted), which are expressed in numerous different tissues. Since all four proteins are structurally conserved SH3 domain-like proteins, it can be assumed that, like MIA/CD-RAP, these proteins are soluble in serum and are widely distributed in the organism. Further analyses of the phenotypes of mice with double, triple, and quadruple defects will be required to assess whether partial redundancy between these genes exists.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the Swedish Medical Research Council to R.F. and from the Deutsche Forschungsgemeinschaft and the Deutsche Krebshilfe to R.B. and A.-K.B.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2.
Bosserhoff, A. K., R. Hein, U. Bogdahn, and R. Buettner. 1996. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein. J. Biol. Chem. 271:490-495.
3.
Bosserhoff, A. K., M. Kaufmann, B. Kaluza, I. Bartke, H. Zirngibl, R. Hein, W. Stolz, and R. Buettner. 1997. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57:3149-3153.
4. Bosserhoff, A. K., S. Kondo, M. Moser, U. Dietz, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, R. Buettner, and L. J. Sandell. 1997. The mouse MIA/CD-RAP gene: structure, chromosomal localization and expression in cartilage and chondrosarcoma. Dev. Dyn. 208:516-525.[CrossRef][Medline]
5. Bosserhoff, A. K., M. Moser, R. Hein, M. Landthaler, and R. Buettner. 1999. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J. Pathol. 187:446-454.[CrossRef][Medline]
6. Bosserhoff, A. K., B. Echtenacher, R. Hein, and R. Buettner. 2001. Functional role of MIA in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 11:417-421.[CrossRef][Medline]
7.
Cohen-Salmon, M., D. Frenz, W. Liu, E. Verpy, S. Voegeling, and C. Petit. 2000. Fdp, a new fibrocyte-derived protein related to MIA/CD-RAP, has an in vitro effect on the early differentiation of the inner ear mesenchyme. J. Biol. Chem. 275:40036-40041.
8.
Dietz, U., and L. J. Sandell. 1996. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J. Biol. Chem. 271:3311-3316.
9. Eggli, P. S., W. Herrmann, E. B. Hunziker, and R. K. Schenk. 1985. Matrix compartments in the growth plate of the proximal tibia of rats. Anat. Rec. 211:246-257.[CrossRef][Medline]
10. Golob, M., R. Buettner, and A. K. Bosserhoff. 2000. Characterization of a transcription factor binding site, specifically activating MIA transcription in melanoma. J. Investig. Dermatol. 115:42-47.[CrossRef][Medline]
11. Guba, M., A. K. Bosserhoff, M. Steinbauer, C. Abels, M. Anthuber, R. Buettner, and K. W. Jauch. 2000. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br. J. Cancer 83:1216-1222.[CrossRef][Medline]
12. Hunziker, E. B., J. Wagner, and D. Studer. 1996. Vitrified articular cartilage reveals novel ultra-structural features respecting extracellular matrix architecture. Histochem. Cell Biol. 106:375-382.[Medline]
13. Hunziker, E. B., M. Nichel, and D. Studer. 1997. Ultrastructure of adult human articular cartilage matrix after cryotechnical processing. Microsc. Res. Tech. 37:271-284.[CrossRef][Medline]
14.
Lougheed, J. C., J. M. Holton, T. Alber, J. F. Bazan, and T. M. Handel. 2001. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc. Natl. Acad. Sci. USA 98:5515-5520.
15. Moser, M., A. Pscherer, A. Imhof, R. Bauer, W. Amselgruber, F. Sinowatz, F. Hofstaedter, R. Schule, and R. Buettner. 1995. Molecular cloning and characterization of a second AP-2 transcription activator gene, AP-2ß. Development 121:2779-2788.[Abstract]
16.
Moser, M., A. Pscherer, C. Roth, J. Becker, G. Mücher, K. Zerres, C. Dixkens, J. Weis, L. Guay-Woodford, R. Buettner, and R. Fässler. 1997. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2ß. Genes Dev. 11:1938-1948.
17.
Müller-Ladner, U., A. K. Bosserhoff, K. Dreher, R. Hein, M. Neidhart, S. Gay, J. Schoelmerich, R. Buettner, and B. Lang. 1999. MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology 38:148-154.
18. Robertson, N. G., S. Heller, J. S. Lin, B. L. Resendes, S. Weremowicz, C. S. Denis, A. M. Bell, A. J. Hudspeth, and C. C. Morton. 2000. A novel conserved cochlear gene, OTOR: identification, expression analysis, and chromosomal mapping. Genomics 66:242-248.[CrossRef][Medline]
19. Sakano, S., Y. Zhu, and L. J. Sandell. 1999. Cartilage-derived retinoic acid-sensitive protein and type II collagen expression during fracture healing are potential targets for Sox9 regulation. J. Bone Miner. Res. 14:1891-1901.[CrossRef][Medline]
20. Stahlecker, J., A. Gauger, A. Bosserhoff, R. Buttner, J. Ring, and R. Hein. 2000. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 20:5041-5044.[Medline]
21. Stoll, R., C. Renner, D. Ambrosius, M. Golob, W. Voelter, R. Buettner, A. K. Bosserhoff, and T. A. Holak. 2000. Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein. J. Biomol. NMR 17:87-88.[CrossRef][Medline]
22. Stoll, R., C. Renner, M. Zweckstetter, M. Brüggert, D. Ambrosius, S. Palme, R. A. Engh, M. Golob, I. Breibach, R. Buettner, W. Voelter, T. A. Holak, and A. K. Bosserhoff. 2001. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J. 20:340-349.[CrossRef][Medline]
23.
van Groningen, J. J., H. P. Bloemers, and G. W. Swart. 1995. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res. 55:6237-6243.
24. Wallin J., J. Wilting, H. Koseki, R. Fritsch, B. Christ, and R. Balling. 1994. The role of Pax-1 in axial skeleton development. Development 120:1109-1121.[Abstract]
25.
Xie, W. F., S. Kondo, and L. J. Sandell. 1998. Regulation of the mouse cartilage-derived retinoic acid-sensitive protein gene by the transcription factor AP-2. J. Biol. Chem. 273:5026-5032.
26. Xie, W. F., X. Zhang, S. Sakano, V. Lefebvre, and L. J. Sandell. 1999. Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein by Sox9. J. Bone Miner. Res. 14:757-763.[CrossRef][Medline]
27. Xie, W. F., X. Zhang, and L. J. Sandell. 2000. The 2.2-kb promoter of cartilage-derived retinoic acid-sensitive protein controls gene expression in cartilage and embryonic mammary buds of transgenic mice. Matrix Biol. 19:501-509.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|